The submission leverages Paradigm Health’s AI-driven infrastructure, which connects community, rural, and academic health systems directly to trial sponsors. By embedding data capture tools into existing electronic health records, the company aims to reduce the administrative burden on clinicians while improving the quality of trial data. The proposed model centers on real-time communication between regulators and sponsors, allowing for faster agreement on endpoints and safety signals.

Interest in the pilot phase is broad, spanning cardiometabolic, oncology, and rare disease research. To date, over 25 provider organizations across the United States have signaled their intent to serve as trial sites. Kent Thoelke, founder and CEO of Paradigm Health, emphasized that the shift is essential to modernize the domestic research ecosystem. This move aligns with the Department of Health and Human Services’ broader Operation Trialblazer, which seeks to secure U.S. leadership in early-stage clinical development. Since April 2026, Paradigm has worked under a landmark collaboration with the FDA to refine these automated reporting mechanisms, aiming to shrink the timeline between initial research and regulatory review.